Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD

Blood (2018) 132 (Supplement 1): 2672.

https://doi.org/10.1182/blood-2018-99-120380

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

Aaron D Goldberg, MD PhD, Robert H. Collins, MD, Richard M. Stone, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, Carlos E Vigil, MD, Eunice S. Wang, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2018-99-117016

Published: 2018

Journal Articles

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Elizabeth A. Griffiths, MD, William Brady, Wei Tan, Carlos E Vigil, MD, James E. Thompson, MD, Laurie A Ford, BS, CCRC, Noelle M Dickey, BS, Jill Sperrazza, BS, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2014) 124 (21): 2318.

https://doi.org/10.1182/blood.V124.21.2318.2318

Published: 2014

Journal Articles

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

Eunice S. Wang, MD, Gerald Fetterly, PhD, William Brady, Wei Tan, Jessica Greene, Allison Gaudy, Carlos E Vigil, MD, Jason H. Mendler, MD, PhD, Michael W. Becker, MD, Kristen O'Dwyer, MD, Jane L. Liesveld, MD, Meir Wetzler, MD

Blood (2013) 122 (21): 2701.

https://doi.org/10.1182/blood.V122.21.2701.2701

Published: 2013

Journal Articles

NADPH Oxidase Regulates Cytarabine-Induced Apoptotic Death in Acute Myeloid Leukemia Cells

Nazmul H Khan, PhD, Kevin J Sexton, Melissa J Grimm, PhD, Brahm H Segal, MD, Carlos E Vigil, MD

Blood (2011) 118 (21): 4258.

https://doi.org/10.1182/blood.V118.21.4258.4258

Published: 2011

Journal Articles

Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients.

Hun Ju Lee, MD, Josephia Muindi, MD, PhD, Tan Wei, MA, Gregory Wilding, Laurie A Ford, BS, CCRC, Sheila Sait, Annmarie Block, PhD, Maurice Barcos, MD, PhD, Carlos E. Vigil, MD, Elizabeth A Griffiths, MD, James E. Thompson, MD, Eunice S. Wang, MD, Candace S. Johnson, PhD, Donald Trump, MD, FACP, Meir Wetzler, MD, FACP

Blood (2010) 116 (21): 1041.

https://doi.org/10.1182/blood.V116.21.1041.1041

Published: 2010

NARROW

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML

A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients

NADPH Oxidase Regulates Cytarabine-Induced Apoptotic Death in Acute Myeloid Leukemia Cells

Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only